Business Context and Reporting Period
This Form 8-K Current Report was filed by Actuate Therapeutics, Inc. (Nasdaq: ACTU) on May 1, 2026. The filing reports the appointment of a new director and the expansion of the Board of Directors. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors expanded from seven (7) to eight (8) members effective May 1, 2026.
- New Appointment: Martin H. Huber, MD, was appointed as a Class III director to fill the newly created seat.
- Committee Assignment: Dr. Huber was assigned to the Nominating and Corporate Governance Committee.
Compensation, Outlook, and Risks
Compensation Arrangements:
- Annual Retainer: $44,000, paid in equal quarterly installments.
- Equity Grant: Initial grant of non-statutory stock options to purchase 30,000 shares of common stock, vesting over a three-year period.
- Consulting Fee: A separate consulting agreement was executed for research and development advisory services with a quarterly fee of $3,000.
- Indemnification: Dr. Huber entered into the Company's standard form indemnification agreement.
Management Commentary and Background: Dr. Huber brings significant experience, having served as President and CEO of Mersana Therapeutics, Inc. (until its acquisition in January 2026) and previously held senior roles at Xilio Therapeutics, TESARO, and Merck. He currently serves on the board of Syndax Pharmaceuticals.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond standard corporate governance disclosures.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 30,000 stock options granted to Dr. Huber in subsequent filings (e.g., Form 4).
- Confirm the total number of authorized board seats and the composition of the Nominating and Corporate Governance Committee.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the appointment.
- Monitor future filings for any changes to the Company's capital structure resulting from the option grant.